US rare disease drug specialist Genzyme, the subject of a hostile takeover offer from France’s Sanofi-Aventis, says that it will …
Genzyme’s predictions on the penalties levied for the ongoing problems at its manufacturing facility in Allston Landing have been confirmed, …
US biotech Genzyme is celebrating FDA approval of its late-onset treatment for Pompe disease Lumizyme. The green light to market …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

